Scientists at Nottingham Trent University are developing a novel device designed to be integrated into a bra, aimed at monitoring breast cancer tumor growth. This development is part of ongoing efforts to enhance the methods available for tracking the progression of breast cancer, a disease that, according to the World Health Organization, is the most prevalent cancer among women globally, affecting 2.1 million women annually and resulting in 670,000 deaths globally in 2022.
The device utilizes a unique electrical current to detect small changes in the fluid surrounding breast cells, which could indicate tumor growth. This technological approach allows for the detection of tumors as small as 2mm, which is significant given the challenges in monitoring breast cancer progression, especially when tumors are small.
By embedding this technology in a bra, the device offers a non-invasive method for continuous monitoring. It is designed to transmit data directly to patients and healthcare providers via smartphones, which could facilitate timely decision-making. However, it’s important to note that while the device presents a new avenue for monitoring, it is yet to be seen how it will compare with existing diagnostic methods in terms of accuracy and reliability.
According to Dr. Yang Wei, a specialist in electronic textiles and electronic engineering at NTU, “the technology would measure changes in breast tissue and help improve a patient’s chance of survival”.
The potential for the device to reduce the frequency of hospital visits could offer convenience and possibly reduce healthcare costs. However, the efficacy and practicality of such a device in real-world settings remain to be fully understood through clinical trials and subsequent adoption in medical practice.
As this technology progresses toward clinical trials, its impact on the standard of care for breast cancer patients will be closely observed. The device represents a step forward in the quest for improved breast cancer monitoring tools, but its ultimate value will be determined by its performance in clinical settings and its ability to integrate with existing healthcare protocols.
